NCT03127592View on ClinicalTrials.gov

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

PHASE3TerminatedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
Pain, Acute
Interventions
DRUG

Fixed Dose Combination

Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg

DRUG

Etodolac

Individual drug

DRUG

Cyclobenzaprine

Individual drug

Trial Locations (1)

13271-130

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos

Sponsors
All Listed Sponsors
lead

Apsen Farmaceutica S.A.

INDUSTRY

NCT03127592 - Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction | Biotech Hunter | Biotech Hunter